镰状细胞病患者接受非心血管手术后的静脉血栓栓塞发生率
回顾性纳入2009年8月至2019年8月在Beaumont Hospitals接受非心血管手术的352例镰状细胞病患者,并按年龄、性别、种族、BMI和手术类型倾向匹配等量无镰状细胞病对照。结果显示两组深静脉血栓、肺栓塞及30天死亡率均无显著差异,镰状细胞病组深静脉血栓诊断时间显著晚于对照组。
要点
- 镰状细胞病患者术后深静脉血栓发生率1.1%,与匹配对照1.4%无显著差异。
- 两组肺栓塞发生率均为0.3%,30天死亡率分别为0.3%和0.9%,无显著差异。
- 镰状细胞病患者深静脉血栓诊断中位时间为术后第12天,显著晚于对照的第5天。
核心结论
- 镰状细胞病患者与非镰状细胞病匹配对照在非心血管手术后的围手术期深静脉血栓、肺栓塞或死亡率无差异。
- 作者认为,对常规静脉血栓栓塞预防措施的警惕性关注似乎有效降低了这些高凝患者的静脉血栓栓塞风险。
- 作者认为,镰状细胞病患者术后可能需要比无镰状细胞病患者更长时间的静脉血栓栓塞预防。
研究设计与样本
- 回顾性病历审查,纳入2009年8月至2019年8月在Beaumont Hospitals接受非心血管手术的352例镰状细胞病患者。
- 按年龄、性别、种族、体重指数和特定手术类型倾向匹配等量无镰状细胞病对照患者。
- 收集的数据包括人口学特征、合并症、所用静脉血栓栓塞预防措施、深静脉血栓和肺栓塞发生情况、住院时长和30天死亡率。
主要发现
- 镰状细胞病组与倾向匹配对照组在年龄、种族、性别、族裔、手术时间或住院时长方面无差异。
- 镰状细胞病组深静脉血栓预防使用率高于对照组(96.0% vs 88.6%;P < .001)。
- 4例镰状细胞病患者(1.1%)发生深静脉血栓,对照组5例(1.4%;P > .999)。
- 每组各1例发生肺栓塞(0.3%;P > .999)。
- 30天死亡率镰状细胞病组1例(0.3%)vs 对照组3例(0.9%;P = .312),无差异。
关键数值与推荐
- 术后≤30天诊断静脉血栓栓塞者中,年龄、性别、种族、体重指数或手术类型无差异。
- 镰状细胞病患者深静脉血栓诊断时间显著晚于对照组(中位术后第12天 vs 第5天;P = .014)。
- 5例发生静脉血栓栓塞的镰状细胞病患者中无吸烟者,6例发生静脉血栓栓塞的非镰状细胞病患者中4例为当前或既往吸烟者(P = .061)。
- 所有发生静脉血栓栓塞的患者在手术时均接受了深静脉血栓预防。
临床怎么用
- 作者认为,对常规静脉血栓栓塞预防措施的警惕性关注似乎有效降低了这些高凝患者的静脉血栓栓塞风险。
- 作者认为,镰状细胞病患者术后可能需要比无镰状细胞病患者更长时间的静脉血栓栓塞预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with sickle cell disease (SCD) will have a baseline hypercoagulable state and an increased risk of venous thromboembolism (VTE). Few data are available regarding the efficacy of standard prophylaxis in preventing VTE after noncardiovascular surgery for patients with SCD. Our objective was to investigate the incidence of VTE in patients with SCD who had undergone noncardiovascular surgery. METHODS: We performed a retrospective medical record review of 352 patients with SCD who had undergone noncardiovascular surgery from August 2009 to August 2019 at Beaumont Hospitals. An equal number of control patients without SCD were propensity matched for age, sex, race, body mass index, and specific surgery. The data collected included demographics, comorbidities, VTE prophylaxis used, occurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE), hospital length of stay, and 30-day mortality. RESULTS: We found no differences in age, race, sex, ethnicity, operative time, or hospital length of stay between the SCD and propensity-matched control patients. DVT prophylaxis was used more frequently for the SCD patients than for the controls (96.0% vs 88.6%; P < .001). Four SCD patients (1.1%) had developed DVT vs five control patients (1.4%; P > .999). One patient in each group had developed PE (0.3%; P > .999). No difference was found in 30-day mortality between the SCD group and the control group (1 [0.3%] vs 3 [0.9%]; P = .312). Of those with a diagnosis of VTE ≤30 days postoperatively, no differences were present in age, sex, race, BMI, or procedure type. DVT had been diagnosed significantly later in the SCD patients than in the controls (median, postoperative day 12 vs 5; P = .014). None of the five SCD patients with VTE was a smoker compared with four of the six non-SCD patients with VTE, who were current or former tobacco users (P = .061). All the patients who had developed VTE had received DVT prophylaxis at surgery. CONCLUSIONS: We found no differences in the perioperative rates of DVT, PE, or mortality between the SCD patients and matched control patients after noncardiovascular surgery. Vigilant attention to routine VTE prophylaxis seemed to effectively reduce the VTE risk for these hypercoagulable patients. SCD patients might need VTE prophylaxis for a longer period postoperatively compared with those without SCD.
引用
- Osei SK, Long GW, Sharrak A, et al. Incidence of venous thromboembolism in patients with sickle cell disease undergoing noncardiovascular surgery. J Vasc Surg Venous Lymphat Disord. 2022. PMID: 36574902. doi:10.1016/j.jvsv.2022.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。